Related Experiment Video
Updated: Jun 13, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Chagas disease
Anis Rassi1, Anis Rassi, José Antonio Marin-Neto
1Division of Cardiology, Anis Rassi Hospital, Goiânia, GO, Brazil. arassijr@terra.com.br
Insights
Chagas disease, a parasitic infection affecting 8 million, has seen improved control through vector management and blood screening. Early detection and novel therapies are crucial for managing this emerging global health issue.
Area of Science:
- Tropical Medicine
- Infectious Diseases
- Parasitology
Background:
- Chagas disease is a chronic parasitic infection caused by Trypanosoma cruzi, endemic in Latin America and affecting approximately 8 million people.
- A significant portion (30-40%) of infected individuals develop severe complications like cardiomyopathy or digestive issues.
- Recent decades show progress in Chagas disease control, yet challenges persist, including its emergence in non-endemic regions.
Purpose of the Study:
- To review recent advancements in Chagas disease management and control.
- To highlight persistent challenges and areas for future research and intervention.
Main Methods:
- Review of epidemiological data and control program outcomes.
- Analysis of current treatment strategies and risk stratification models.
- Discussion of emerging trends and unmet needs in Chagas disease management.
Main Results:
- Vector control and blood donor screening have successfully reduced Chagas disease incidence and prevalence.
- Current treatments like benznidazole and nifurtimox are effective and recommended for a broader patient group.
- Improved risk stratification models aid in guiding treatment to potentially halt or reverse disease progression.
Conclusions:
- While control measures have improved, Chagas disease remains a significant public health concern, particularly due to population mobility.
- Early detection and treatment of asymptomatic cases are underutilized.
- Further research is needed to assess novel therapies and address the global spread of Chagas disease.
Abstract:
Chagas disease is a chronic, systemic, parasitic infection caused by the protozoan Trypanosoma cruzi, and was discovered in 1909. The disease affects about 8 million people in Latin America, of whom 30-40% either have or will develop cardiomyopathy, digestive megasyndromes, or both. In the past three decades, the control and management of Chagas disease has undergone several improvements. Large-scale vector control programmes and screening of blood donors have reduced disease incidence and prevalence. Although more effective trypanocidal drugs are needed, treatment with benznidazole (or nifurtimox) is reasonably safe and effective, and is now recommended for a widened range of patients. Improved models for risk stratification are available, and certain guided treatments could halt or reverse disease progression. By contrast, some challenges remain: Chagas disease is becoming an emerging health problem in non-endemic areas because of growing population movements; early detection and treatment of asymptomatic individuals are underused; and the potential benefits of novel therapies (eg, implantable cardioverter defibrillators) need assessment in prospective randomised trials.
Related Concept Videos
American Trypanosomiasis
Leishmaniasis
Cholera
Esophageal Achalasia
Toxoplasmosis
Giardiasis

